{
    "symbol": "RDHL",
    "quarter": 1,
    "year": 2022,
    "date": "2022-06-23 13:25:20",
    "content": "  This conference call may contain projections or other forward-looking statements regarding future events or the future performance of RedHill, including statements with respect to the business, financial results, operational cost savings, promotion and other efforts related to RedHill's commercialization activity, potential acquisitions and the initiation, timing, progress and results of RedHill's research, manufacturing, preclinical studies, clinical trials, marketing applications and approvals, if any, including the clinical trials of opaganib and RHB-107 for the treatment of COVID-19 and RHB-204 for NTM disease."
}